{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:04:25Z","timestamp":1792087465101,"version":"4.4.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with cancer have an increased risk of thromboembolism, which is the second leading cause of death in these patients. Several mechanisms of the prothrombotic state in these patients have been proposed. Among them are a platelet activation receptor, C-type lectin-like receptor 2 (CLEC-2), and its endogenous ligand podoplanin, which are the focus of this review. CLEC-2 is almost specifically expressed in platelets\/megakaryocytes in humans. A membrane protein, podoplanin is expressed in certain types of cancer cells, including squamous cell carcinoma, brain tumor, and osteosarcoma, in addition to several normal tissues, including kidney podocytes and lymphatic endothelial cells but not vascular endothelial cells. In the bloodstream, podoplanin induces platelet activation by binding to CLEC-2 and facilitates hematogenous cancer metastasis and cancer-associated thrombosis. In an experimental lung metastasis model, the pharmacological depletion of CLEC-2 from platelets in mice resulted in a marked reduction of lung metastasis of podoplanin-expressing B16F10 cells. Control mice with B16F10 orthotopically inoculated in the back skin showed massive thrombus formation in the lungs, but the cancer-associated thrombus formation in CLEC-2\u2013depleted mice was significantly inhibited, suggesting that CLEC-2\u2013podoplanin interaction stimulates cancer-associated thrombosis. Thromboinflammation induced ectopic podoplanin expression in vascular endothelial cells or macrophages, which may also contribute to cancer-associated thrombosis. CLEC-2 depletion in cancer-bearing mice resulted in not only reduced cancer-associated thrombosis but also reduced levels of plasma inflammatory cytokines, anemia, and sarcopenia, suggesting that cancer-associated thrombosis may cause thromboinflammation and cancer cachexia. Blocking CLEC-2\u2013podoplanin interaction may be a novel therapeutic strategy in patients with podoplanin-expressing cancer.<\/jats:p>","DOI":"10.1182\/hematology.2019001388","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T15:19:34Z","timestamp":1575645574000},"page":"175-181","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":24,"title":["Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin"],"prefix":"10.1182","volume":"2019","author":[{"given":"Katsue","family":"Suzuki-Inoue","sequence":"first","affiliation":[{"name":"Department of Clinical and Laboratory Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"13","key":"2019120610124889700_B1","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2017-03-743211","article-title":"Cancer-associated pathways and biomarkers of venous thrombosis","volume":"130","author":"Hisada","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2019120610124889700_B2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jjcc.2018.02.011","article-title":"Mechanism and management of cancer-associated thrombosis","volume":"72","author":"Mukai","year":"2018","journal-title":"J Cardiol"},{"issue":"10","key":"2019120610124889700_B3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/cancers10100380","article-title":"Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment","volume":"10","author":"Abdol Razak","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2019120610124889700_B4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1172\/JCI200318882","article-title":"Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas","volume":"112","author":"Wahrenbrock","year":"2003","journal-title":"J Clin Invest"},{"issue":"15","key":"2019120610124889700_B5","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1182\/blood-2011-07-368514","article-title":"Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome","volume":"118","author":"Shao","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019120610124889700_B6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/jth.13951","article-title":"Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients","volume":"16","author":"Mauracher","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019120610124889700_B7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/bjh.15906","article-title":"Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer","volume":"186","author":"Grilz","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"2019120610124889700_B8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2019120610124889700_B9","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1080\/09537104.2018.1478401","article-title":"Roles of the CLEC-2\u2013podoplanin interaction in tumor progression","volume":"29","author":"Suzuki-Inoue","year":"2018","journal-title":"Platelets"},{"issue":"6","key":"2019120610124889700_B10","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.smim.2016.10.011","article-title":"Hypercoagulation and complement: connected players in tumor development and metastases","volume":"28","author":"Guglietta","year":"2016","journal-title":"Semin Immunol"},{"issue":"1","key":"2019120610124889700_B11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/cancers11010071","article-title":"Recent advances in the management of cancer-associated thrombosis: new hopes but new challenges","volume":"11","author":"Frere","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2019120610124889700_B12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"2019120610124889700_B13","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019120610124889700_B14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"2019120610124889700_B15","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"2019120610124889700_B16","doi-asserted-by":"crossref","first-page":"814","DOI":"10.7326\/M15-2117","article-title":"Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force","volume":"164","author":"Chubak","year":"2016","journal-title":"Ann Intern Med"},{"issue":"3","key":"2019120610124889700_B17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc.2016.4","article-title":"Aspirin and colorectal cancer: the promise of precision chemoprevention","volume":"16","author":"Drew","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2019120610124889700_B18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2018-06-860874","article-title":"Arterial thromboembolic events preceding the diagnosis of cancer in older persons","volume":"133","author":"Navi","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2019120610124889700_B19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10555-017-9672-2","article-title":"Platelet-activating factor podoplanin: from discovery to drug development","volume":"36","author":"Takemoto","year":"2017","journal-title":"Cancer Metastasis Rev"},{"issue":"36","key":"2019120610124889700_B20","doi-asserted-by":"crossref","first-page":"25993","DOI":"10.1074\/jbc.M702327200","article-title":"Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells","volume":"282","author":"Suzuki-Inoue","year":"2007","journal-title":"J Biol Chem"},{"issue":"2","key":"2019120610124889700_B21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/jth.13590","article-title":"Physiologic and pathophysiologic roles of interaction between C-type lectin-like receptor 2 and podoplanin: partners from in utero to adulthood","volume":"15","author":"Suzuki-Inoue","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019120610124889700_B22","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood-2005-05-1994","article-title":"A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2","volume":"107","author":"Suzuki-Inoue","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019120610124889700_B23","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1002\/eji.201445314","article-title":"The expression of mouse CLEC-2 on leucocyte subsets varies according to their anatomical location and inflammatory state","volume":"45","author":"Lowe","year":"2015","journal-title":"Eur J Immunol"},{"issue":"1","key":"2019120610124889700_B24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1349-7006.2007.00634.x","article-title":"Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2","volume":"99","author":"Kato","year":"2008","journal-title":"Cancer Sci"},{"issue":"12","key":"2019120610124889700_B25","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.str.2014.09.009","article-title":"A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin","volume":"22","author":"Nagae","year":"2014","journal-title":"Structure"},{"issue":"26","key":"2019120610124889700_B26","doi-asserted-by":"crossref","first-page":"22241","DOI":"10.1074\/jbc.M111.329987","article-title":"Platelet activation receptor CLEC-2 regulates blood\/lymphatic vessel separation by inhibiting proliferation, migration, and tube formation of lymphatic endothelial cells","volume":"287","author":"Osada","year":"2012","journal-title":"J Biol Chem"},{"issue":"52","key":"2019120610124889700_B27","doi-asserted-by":"crossref","first-page":"35695","DOI":"10.1074\/jbc.M114.584284","article-title":"Syk and Src family kinases regulate C-type lectin receptor 2 (CLEC-2)-mediated clustering of podoplanin and platelet adhesion to lymphatic endothelial cells","volume":"289","author":"Pollitt","year":"2014","journal-title":"J Biol Chem"},{"issue":"7523","key":"2019120610124889700_B28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature13814","article-title":"Dendritic cells control fibroblastic reticular network tension and lymph node expansion","volume":"514","author":"Acton","year":"2014","journal-title":"Nature"},{"issue":"1","key":"2019120610124889700_B29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ni.3035","article-title":"The CLEC-2-podoplanin axis controls the contractility of fibroblastic reticular cells and lymph node microarchitecture","volume":"16","author":"Astarita","year":"2015","journal-title":"Nat Immunol"},{"issue":"3","key":"2019120610124889700_B30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/jth.13604","article-title":"C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice","volume":"15","author":"Shirai","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"13","key":"2019120610124889700_B31","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2016-06-720714","article-title":"Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism","volume":"129","author":"Riedl","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2019120610124889700_B32","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2017-02-763524","article-title":"Risking thromboembolism: podoplanin and glioma","volume":"129","author":"Zwicker","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2019120610124889700_B33","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2016-09-742999","article-title":"Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis","volume":"129","author":"Payne","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2019120610124889700_B34","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1182\/blood-2017-02-764670","article-title":"CLEC-2\/podoplanin and thromboinflammation","volume":"129","author":"Suzuki-Inoue","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2019120610124889700_B35","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1172\/JCI79070","article-title":"Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets","volume":"125","author":"Hitchcock","year":"2015","journal-title":"J Clin Invest"},{"issue":"4","key":"2019120610124889700_B36","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.cell.2010.01.045","article-title":"Lymphangiogenesis: molecular mechanisms and future promise","volume":"140","author":"Tammela","year":"2010","journal-title":"Cell"},{"key":"2019120610124889700_B37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fimmu.2012.00283","article-title":"Podoplanin: emerging functions in development, the immune system, and cancer","volume":"3","author":"Astarita","year":"2012","journal-title":"Front Immunol"},{"issue":"4","key":"2019120610124889700_B38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/neuonc\/nos055","article-title":"Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation","volume":"14","author":"Peterziel","year":"2012","journal-title":"Neuro Oncol"},{"issue":"2","key":"2019120610124889700_B39","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.ajpath.2011.04.027","article-title":"Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma","volume":"179","author":"Kunita","year":"2011","journal-title":"Am J Pathol"},{"issue":"17","key":"2019120610124889700_B40","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1158\/0008-5472.CAN-08-0299","article-title":"Podoplanin is a novel Fos target gene in skin carcinogenesis","volume":"68","author":"Durchdewald","year":"2008","journal-title":"Cancer Res"},{"issue":"5","key":"2019120610124889700_B41","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.ajpath.2018.01.016","article-title":"Inflammatory cytokines induce podoplanin expression at the tumor invasive front","volume":"188","author":"Kunita","year":"2018","journal-title":"Am J Pathol"},{"issue":"25","key":"2019120610124889700_B42","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1182\/blood.2018877043","article-title":"Inhibition of platelet GPVI induces intratumor hemorrhage and increases efficacy of chemotherapy in mice","volume":"133","author":"Volz","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2019120610124889700_B43","first-page":"908","article-title":"Platelet ITAM signaling is critical for vascular integrity in inflammation","volume":"123","author":"Boulaftali","year":"2013","journal-title":"J Clin Invest"},{"key":"2019120610124889700_B44","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1038\/srep05924","article-title":"A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin","volume":"4","author":"Kato","year":"2014","journal-title":"Sci Rep"},{"issue":"5","key":"2019120610124889700_B45","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1161\/ATVBAHA.112.300672","article-title":"Combined in vivo depletion of glycoprotein VI and C-type lectin-like receptor 2 severely compromises hemostasis and abrogates arterial thrombosis in mice","volume":"33","author":"Bender","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"32","key":"2019120610124889700_B46","doi-asserted-by":"crossref","first-page":"24494","DOI":"10.1074\/jbc.M110.130575","article-title":"Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic\/neonatal lethality of CLEC-2-deficient mice by blood\/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets","volume":"285","author":"Suzuki-Inoue","year":"2010","journal-title":"J Biol Chem"},{"issue":"40","key":"2019120610124889700_B47","doi-asserted-by":"crossref","first-page":"42733","DOI":"10.18632\/oncotarget.5811","article-title":"Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis","volume":"6","author":"Chang","year":"2015","journal-title":"Oncotarget"},{"issue":"17","key":"2019120610124889700_B48","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1182\/bloodadvances.2018016261","article-title":"Cobalt hematoporphyrin inhibits CLEC-2-podoplanin interaction, tumor metastasis, and arterial\/venous thrombosis in mice","volume":"2","author":"Tsukiji","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"2019120610124889700_B49","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/jth.13987","article-title":"Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC\u20102\/podoplanin\u2010dependent platelet aggregation and lung metastasis","volume":"16","author":"Sasaki","year":"2018","journal-title":"J Thromb Haemost"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/175\/1546270\/hem2019001388c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/175\/1546270\/hem2019001388c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T07:08:38Z","timestamp":1722150518000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2019\/1\/175\/422639\/Platelets-and-cancerassociated-thrombosis-focusing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2019001388","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]}}}